At the last check on Thursday, BioNexus Gene Lab Corp.’s (NASDAQ:BGLC) stock was up $0.66, moving up 91.67 percent to $1.38. The average number of shares traded per day over the past five days has been 1,704,507 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0250 fall in that time frame. In the last twenty days, the average volume was 2,707,281, while in the previous 50 days, it was 1,141,626.
Since last month, BGLC stock retreated -87.36%. Shares of the company fell to $0.6505 on 08/16/23, the lowest level in the past month. A 52-week high of $17.88 was reached on 07/12/23 after having rallying from a 52-week low of $0.65. Since the beginning of this year, BGLC’s stock price has dropped by -87.89% or -$10.2850, and marked a new high 3 times. However, the stock has declined by -92.28% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
The stock’s beta is 0.89. Besides these, the trailing price-to-sales (P/S) ratio of 2.13, the price-to-book (PB) ratio of 3.07, and the price-to-cash flow ratio of 43.92 may also be considered.
Financial Health
In the recent quarter, BioNexus Gene Lab Corp.’s quick ratio stood at 2.90, while its current ratio was 3.50, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 12.20% percent. In the recent year, EBITDA margin amounted to -3.34%, whereas operating margins totaled -3.60%.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -5.30%. Return on equity (ROE) for the past 12 months was -6.70%.
Technical Picture
This quick technical analysis looks at BioNexus Gene Lab Corp.’s (BGLC) price momentum. With a historical volatility rate of 316.52%, the RSI 9-day stood at 36.00% on 16 August.
With respect to its five-day moving average, the current BioNexus Gene Lab Corp. price is down by -2.19% percent or -$0.0250. At present, BGLC shares trade -77.10% below its 20-day simple moving average and -90.71% percent below its 100-day simple moving average. However, the stock is currently trading approximately -70.03% below its SMA50 and -94.30% below its SMA200.
Stochastic coefficient K was 8.57% and Stochastic coefficient D was 3.46%, while ATR was 0.8637. Given the Stochastic reading of 22.89% for the 14-day period, the RSI (14) reading has been calculated as 38.97%. As of today, the MACD Oscillator reading stands at -0.1950, while the 14-day reading stands at -0.5362.
Analyst Ratings
BioNexus Gene Lab Corp. (BGLC) has been rated – by analysts. According to 0 brokerage firms, BGLC is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate BioNexus Gene Lab Corp. stock as buy, with 0 recommending it as overweight.
